Liraglutide rescues beta-cell defects in Wolfram syndrome iPSC-derived cells through GLP-1R signaling | Research

The takeaway

In Wolfram syndrome 1 iPSC-derived beta-cells, liraglutide normalized calcium handling, enhanced insulin processing (↑PC1/3), restored secretory function (↑SNAP25), and reduced apoptosis by modulating the unfolded protein response—supporting GLP-1R as a WS1 therapeutic target.

All defects rescued
Liraglutide normalized calcium, insulin processing, secretion, and apoptosis in Wolfram syndrome iPSC β-cells—supporting GLP-1 drugs as the first disease-modifying WS1 therapy

What the researchers found

WS1 iPSC β-cells: ↓insulin processing (proinsulin accumulation, ↓PC1/3), dysregulated Ca²⁺ (altered CACNA1D), ↓SNAP25, ↑autophagy, ↑cytokine-induced apoptosis. Liraglutide: normalized Ca²⁺, ↑insulin processing/secretion, ↓apoptosis. Mechanism: UPR modulation. c.316-1G>A and c.757A>T mutations.

Why it matters

Wolfram syndrome has no treatment. Demonstrating liraglutide rescues mutation-specific β-cell defects in patient-derived cells provides a strong rationale for personalized GLP-1 therapy in this devastating genetic disease.

How the study worked

Patient-derived iPSC β-cells (WFS1 c.316-1G>A/c.757A>T). Insulin processing, Ca²⁺ imaging, secretory function, autophagy, apoptosis assays. Liraglutide treatment. UPR analysis.

What this study cannot tell us

In vitro iPSC model. Specific WFS1 mutations—may not apply to all WS1 variants. β-cell focus does not address WS1 neurological or optic features. Long-term effects unknown.

How to read the evidence

In vitro patient-derived iPSC study. Strong precision medicine evidence for this specific mutation.

When this study was published

Published in 2025.

The bigger picture

This exemplifies precision medicine: using patient-derived iPSCs to identify mutation-specific defects and test drugs. GLP-1 therapy could become the first disease-modifying treatment for Wolfram syndrome.

Questions still open

Should all WS1 patients trial GLP-1 agonists?
Which WFS1 mutation types would respond best to GLP-1R therapy?
Could liraglutide prevent β-cell loss if started early in WS1?

Common questions

What is Wolfram syndrome?

Wolfram syndrome 1 is a rare genetic disorder caused by WFS1 gene mutations that leads to childhood-onset diabetes, progressive vision loss, and neurological problems. There is currently no disease-modifying treatment. This study shows a diabetes drug (liraglutide) can fix the specific cellular defects caused by the mutations.

Could GLP-1 drugs treat Wolfram syndrome?

This study provides strong laboratory evidence that they could. Liraglutide fixed all the identified defects in insulin-producing cells derived from Wolfram syndrome patients—improving calcium signaling, insulin production, secretion, and cell survival. Clinical trials are the logical next step.

Read the original research

Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.

Diabetes, 74(7), 1273-1288

View on PubMed ↗Publisher’s paper ↗

Citation

Torchio, Silvia; Siracusano, Gabriel; Cuozzo, Federica; Zamarian, Valentina; Pellegrini, Silvia; Manenti, Fabio; Bonfanti, Riccardo; Frontino, Giulio; Sordi, Valeria; Chimienti, Raniero; Piemonti, Lorenzo. (2025). Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.. Diabetes, 74(7), 1273-1288. https://doi.org/10.2337/db24-0720